Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213736 | 0.93 | CRHR1 (0.37) | CRHR1GLANPC1RAB9AMEN1 | |
| SCHEMBL7213693 | 0.86 | FFAR2 (0.38) | CRHR1FFAR2NPC1RAB9AMEN1 | |
| SCHEMBL7220814 | 0.85 | CRHR1 (0.40) | CRHR1FFAR2 | |
| SCHEMBL7220146 | 0.82 | CRHR1 (0.32) | CRHR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL7219574 | 0.82 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL7215955 | 0.81 | SLC6A2 (0.35) | CRHR1FFAR2 | |
| SCHEMBL7214523 | 0.81 | NPC1 (0.35) | CRHR1GLANPC1RAB9AMEN1 | |
| SCHEMBL7219415 | 0.80 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL7213735 | 0.79 | CYP17A1 (0.33) | GLANPC1RAB9AMEN1KMT2A | |
| SCHEMBL7214751 | 0.78 | CRHR1 (0.37) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589958-B1 | Treatment of psychiatric disorders and neurological diseases including affective disorder, anxiety, stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-08 | — | — | US | claimed |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-19 | — | — | US | claimed |
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | claimed |
| US-6294671-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | DUPONT PHARMACEUTICALS COMPANY | 2001-09-25 | — | — | US | claimed |
| US-6589958-B1 | Treatment of psychiatric disorders and neurological diseases including affective disorder, anxiety, stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-19 | — | — | US | disclosed |
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| US-6294671-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | DUPONT PHARMACEUTICALS COMPANY | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | CRHR1, P2RX5, P2RX1 | CRHR1 1/4885FFAR2 459/4885GLA 4850/4885 |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | CRHR1, P2RX5, P2RX1 | CRHR1 1/4885FFAR2 459/4885GLA 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.